India Pharma Outlook Team | Wednesday, 01 July 2026
AI drug discovery is gaining momentum as pharmaceutical companies look for faster and more efficient ways to develop new medicines.
The latest example comes from Mankind Pharma, which has entered into a strategic partnership with Denovo Sciences to strengthen its AI drug discovery capabilities.
The collaboration reflects a growing trend in the pharmaceutical industry, where companies are increasingly using artificial intelligence to improve research, reduce development time, and identify promising drug candidates more efficiently.
The partnership marks another step in Mankind Pharma's efforts to expand its innovation-driven research portfolio. By combining Denovo Sciences' AI platform with its own pharmaceutical expertise, the company aims to improve the early stages of drug discovery, where identifying the right molecules has traditionally been time-consuming and expensive.
The pharmaceutical industry has been under pressure to develop new treatments faster while keeping research costs under control. Developing a new medicine often takes more than a decade, and many potential drugs fail before reaching clinical trials.
This is where artificial intelligence is making a difference.
AI-powered platforms can process large volumes of biological, chemical, and clinical data in a fraction of the time required through traditional research methods. These systems help researchers identify potential drug targets, predict how molecules may behave, and shortlist the most promising compounds for laboratory testing.
Some of the key advantages of AI drug discovery include:
Although laboratory testing and clinical trials remain essential, AI is helping researchers make better decisions before drugs enter these expensive stages.
Also Read: How to Apply for India's Rs 10,000 Crore Biopharma SHAKTI Scheme
Under the strategic collaboration, Mankind Pharma will leverage Denovo Sciences' AI-powered drug discovery platform to accelerate the identification and development of novel drug candidates.
The partnership is expected to strengthen the company's research capabilities while supporting its long-term focus on innovation. Instead of relying solely on conventional research methods, the company plans to use advanced machine learning and predictive analytics to improve the discovery process.
The move also reflects a broader shift in the pharmaceutical sector, where AI-driven collaborations are becoming increasingly common. Drugmakers are working with technology companies to improve research productivity, shorten development timelines, and increase the chances of identifying successful drug candidates.
The agreement between Mankind Pharma and Denovo Sciences comes at a time when AI in pharma is attracting growing investment across global markets. Leading pharmaceutical companies are adopting AI across multiple stages of drug development, including target identification, molecule design, toxicity prediction, and clinical research planning.
Industry experts believe these collaborations could help reduce failures in early research while improving the speed of innovation. As AI technologies continue to evolve, partnerships between pharmaceutical companies and AI specialists are expected to play a larger role in bringing new therapies to patients.
For Mankind Pharma, the partnership is more than a technology upgrade. It signals the company's intent to strengthen its research capabilities and become part of the industry's shift toward data-driven drug discovery.
As pharmaceutical companies continue exploring new ways to improve R&D productivity, AI drug discovery is likely to become a key driver of innovation, helping researchers identify promising medicines faster while reducing both time and development costs.
.jpg)
